|
All participants |
(N=20) |
|
Number of participants with TEAEs |
20 (100%) |
Number of participants with Treatment-Related TEAEs* |
17
(85%) |
Number of participants with Moderate or Severe TEAEs |
9
(45%) |
Number of participants with Treatment-Related*, Moderate or Severe TEAEs |
7 (35%) |
Number of Treatment-Emergent Adverse Events |
249 |
Number of Treatment-Related* TEAEs |
176 |
Number of Moderate or Severe TEAEs |
22 |
Number of Treatment-Related*, Moderate or Severe TEAEs |
12 |
Number of TEAE per participant |
12.45 |
Number of Treatment-Related* TEAEs per participant |
8.8 |
Number of Moderate or Severe TEAEs per participant |
1.1 |
Number of Treatment-Related*, Moderate or Severe TEAEs per participant |
0.6 |